The Drug Discovery Services Companies Quadrant provides an in-depth analysis of the drug discovery services market, highlighting key players, technological advancements, and trends. Conducted by ...

Beam Therapeutics' said the Food and Drug Administration granted generative medicine advanced therapy designation to its sickle cell disease treatment BEAM-101.

Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene ...

Wa'el Hashad Wa'el Hashad, CEO, Longeveron Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating ...

In August 2025, Seagen announced a studies how well tucatinib works for solid tumors that make either more HER2 or a ...

Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment ...

In August 2025, NexEos Diagnostics Inc . announced phase 2 study to assess the safety and exploratory diagnostic performance ...

Hatteras was founded in 2000 with the closing of Hatteras Venture Partners I, a seed-stage venture fund with $2.93 million in capital. Today, the firm is focused on seed- and early stage companies in ...

Key highlights Lundbeck's total revenue grew by +14% CER[1] (+14% DKK) to DKK 12,258 million in the first six months of 2025. Growth in the U.S. and Europe was the driver of this strong performance. U ...

This marks the world's first registrational clinical trial evaluating an immunotherapy monotherapy for extrapulmonary neuroendocrine carcinoma (EP-NEC). The study, led by Professo ...

DYNE-251 received FDA breakthrough therapy designation, showcasing its potential for patients with Duchenne muscular ...

Key Points EPS (GAAP) matched estimates at $(0.26), reflecting cost controls but ongoing net losses and no revenue. Positive clinical milestones achieved for BX211 (diabetic foot osteomyelitis) and ...